Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics

Drug Profile

Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics

Alternative Names: SB-LSD3; SB-LSD4; ZFN Bcl11a; ZFN therapeutics - Sangamo; ZFP nucleases - Sangamo

Latest Information Update: 31 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics; University of Massachusetts Medical School
  • Class Antineoplastics; Cell therapies; Gene therapies; Stem cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Alpha 1 antitrypsin modulators; CCR5 receptor modulators; Cell replacements; Gene modulators; Gene silencing; Genetic transcription inhibitors; Interleukin 2 receptor modulators; T-cell receptor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity No

Highest Development Phases

  • No development reported Alpha 1-antitrypsin deficiency; Cancer; Down syndrome; HIV infections; Immunodeficiency disorders; Mucopolysaccharidosis I; Mucopolysaccharidosis II

Most Recent Events

  • 22 Feb 2022 Sangamo Therapeutics has multiple patents protection for zinc finger DNA-binding protein nucleases in USA
  • 07 Feb 2018 Case Western Reserve University and Sangamo Therapeutics plans a phase I trial for HIV infections in USA in 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top